CYCART-201

N/A

Report date: 2023/06/14 16:38:02

Base Information

Drug NameCYCART-201

Drug Alias NameCYCART-201

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacements

TargetsNot applicable

Therapy Area/IndicationsSolid tumoursLymphoma, Mantle-CellLymphoma, Non-Hodgkin

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesCelularity Inc

China Registration ClassN/A

Develop Information

Active CompaniesCelularity Inc

Inactive CompaniesN/A

Active IndicationsSolid tumoursLymphoma, Mantle-CellLymphoma, Non-Hodgkin

Inactive IndicationsN/A

Other Information

ATC CodeN/A